|Articles|March 7, 2019

Almac Group Announces Almac ONE for Supply Chain

Almac Group announced Almac ONE™, a new clincal trial supply solution. The solution works as part of the clinical supply chain creating a responsive end-to-end process throughout the lifecycle of a clinical study

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
September 16th 2025
Atom Therapeutics Launches Global Phase II Trial of Novel Anti-Inflammatory Treatment for Acute Gout Flares
September 16th 2025
Operational Strategies That Strengthened the NIMBLE Trial Design
September 16th 2025
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
September 15th 2025
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
September 15th 2025

Almac Group Announces Almac ONE for Supply Chain

Newsletter

Related Articles

Trending on Applied Clinical Trials Online

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

Atom Therapeutics Launches Global Phase II Trial of Novel Anti-Inflammatory Treatment for Acute Gout Flares